稳心颗粒联合β受体阻滞剂治疗冠心病并发室性早搏患者的临床疗效观察

The Clinical efficacy of Wenxinkeli joint βblocker therapy in patients of coronary heart disease with ventricular premature beats

目的探讨稳心颗粒与β受体阻滞剂美托洛尔联合治疗冠心病并发室性早搏患者的临床疗效。方法我院2009年1月至2011年12月收治的冠心病并发室性早搏患者126例,随机分为两组,观察组60例(W组)和对照组66例(A组),观察组患者给予稳心颗粒和美托洛尔治疗,对照组给予胺碘酮治疗,两组患者均治疗4周。结果 W组临床症状显效率和总有效率分别为68.3%和90.0%,明显高于A组的54.5%和81.8%;W组心电图总有效率为93.3.0%高于A组的84.8%,差异均有统计学意义(P【0.05),W组心电图显效率为66.7%,与A组的63.6%,差异无统计学意义(P】0.05)。结论稳心颗粒联合β受体阻滞剂美托洛尔能够显著改善冠心病并发室性早搏患者的临床症状,且无致心律失常作用,安全性高,值得临床借鉴。

Objective To investigate the clinical efficacy of the Wenxinkeli and β-blocker metoprolol treatment of coronary artery disease complicated by premature ventricular contractions. Methods Coronary heart disease hospital in 2009 from January to December 2011 concurrent premature ventricular contractions in patients with 126 cases were randomly divided into two groups to observe a group of 60 patients (M group) and a control group of 66 cases (group A) . The control group was given amiodarone treatment,observed in patients given the metoprolol Wenxinkeli treatment,two groups of patients were treated for 4 weeks. Results Remarkable efficiency of the clinical symptoms of the W group and total efficiency of 68. 3% and 90. 0% respectively,significantly higher than 54. 5% and 81. 8% in group A; W electrocardiogram total effective rate was 93.3.0% from 84.8% in Group A,the differencewere statistically significant (P < 0.05) W group ECG markedly effective rate was 66. 7% and 63. 6% in group A,the difference was not statistically significant (P > 0.05) . Conclusion Wenxinkeli combined with β blockers metoprolol can significantly improve coronary heart disease with ventricular premature beats in patients with clinical symptoms,significant clinical effect,and no arrhythmogenic effect,safe,worthy of clinical learn.